Vitargo Biosciences Submits IPO Prospectus Following $50M+ Series A Financing to Advance In Vivo CAR-T Pipeline
Vivacta
Cell Therapy Researcher
Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
PharmCube has learned:IVACTA Biotechnology was founded on June 25, 2025, as a spin-off of the in vivo CAR-T platform from Beijing Gracell Biomedicines Co., Ltd. ("Gracell Biomedicines"). IVACTA Biotechnology is developing an in vivo CAR-T pipeline based on targeted LNP delivery systems, focusing on bringing revolutionary treatments to hematological malignancies and autoimmune diseases.
At the same time, IVACTA Biotechnology's delivery system based on targeted LNP stands out in terms of precision, safety, and production compatibility. It enhances T-cell targeting efficiency through a unique technical approach, effectively reduces off-target risks, and adapts to scaled preparation. The self-developed targeting technology achieves efficient T-cell activation and long-term CAR expression, demonstrating excellent B-cell depletion effects in multiple preclinical models, with good safety upon repeated dosing.
The first candidate product has entered clinical trials and has already obtained positive preliminary human data.
This round of financing will accelerate the clinical validation of IVACTA Biotechnology and its in vivo CAR-T pipeline.
Rooted in Shanghai and radiating globally, PharmaCircle, as a strategic platform for the biopharmaceutical industry, is committed to the mission of "enabling the boundless flow of intelligence and connections." It has built a comprehensive empowerment system covering the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource linking, industry think tanks, and ecosystem communities—it establishes the infrastructure for value flow within China's pharmaceutical sector.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises' leapfrog growth.
